anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: organic synthesis. SUBSTANCE: invention provides novel amine derivatives of general formula I:   (I), where R 1  represents carbamoyl group optionally containing one or two alpha-substituents (described below), thiocarbamoyl group optionally containing one or two alpha-substituents (described below), sulfonyl group containing one alpha-substituent (described below), or carbonyl group containing one alpha- substituent (described below); R 2  represents hydrogen atom; R 3  C1-C10-alkyl group; W 1 ,W 2  and W 3 , each represents ordinary bond or C1-C8-alkylene group; X represents oxygen or sulfur atom; Y oxygen atom; Q sulfur atom; X group = CH- or nitrogen atom; Ar benzene or naphthalene ring; L represents 1-2 substituents in Ar ring, each being hydrogen or C1-C6-alkyl; alpha-substituents can be C1-C10-alkyl, C3-C10-cycloalkyl, or phenyl optionally substituted by 1-3 gamma-substituents (described below), etc.; gamma- substituents can be C1-C6-alkyl, halo-C1-C6-alkyl, C1-C6-alkoxy, halogen, hydroxy, cyano, nitro, or alkylenedioxy group; or their pharmaceutically acceptable salt or esters. Pharmaceutical composition exhibiting PPARγ- activating effect includes a compound I or its pharmaceutically acceptable salt or ester derivative in effective amount along with carrier or diluent. Agent containing compound I or its pharmaceutically acceptable salt or ester derivative is suitable for treatment of cancer. Treatment or prevention of cancer in warm-blooded animals consists in administration of effective amount of compound I or its pharmaceutically acceptable salt or ester derivative optionally in combination with PXR activator. EFFECT: extended choice of biologically active compounds with PPARγ-activating effect. 36 cl, 7 tbl, 109 ex
Adhesive compositions comprising alphacyano acrylic esters containing no alpha-cyanoacetic esters (see Division C2) are suitable for forming bonds between stainsless steel, glass, human skin, bones, teeth.  The monomer autopolymerizes on being pressed into a thin film between the bonding surfaces.  There may be present in the compositions an acidic stabilizer, e.g. P2O5, carboxylic acids, BF3, SO2, NO, HF, SnCl4 or Lewis bases, or the formulations may include polymers, e.g. acrylates, cyanoacrylates, cellulose esters, and plasticizers of the organic ester type.  Particularly useful are the a -cyanoacrylates of up to C8 alkanols or alkenols, cyclohexanol and phenol.  The examples refer.ALSO:Adhesive compositions comprising alphacyanoacrylic esters containing no alphacyanoacetic esters (see Division C2) are suitable for forming bonds between stainless steel, glass, human skin, bones, teeth.  The monomer autopolymerizes on being pressed into a thin film between the bonding surfaces.  There may be present in the compositions an acidic stabilizer, e.g. P2O5, carboxylic acids, BF3, SO2, NO, HF, SnCl4 or Lewis bases, or the formulations may include polymers, e.g. acrylates, cyanoacrylates, cellulose esters, and plasticizers of the organic ester type. Particularly useful are the a -cyanoacrylates of up to C8 alkanols or alkenols, cyclohexanol and phenol.  The examples refer.ALSO:A product of improved shelf life is obtained in the preparation of alphacyanoacrylic esters according to the parent Specification by the improvement in the pyrolytic depolymerization of the intermediate under vacuum and in the presence of an inhibitor, the improvement consisting of carrying out periodic analysis of the product, preferably by gas chromatography, at different pyrolysis temperatures and retaining only those samples free from alpha cyanoacetic esters. The preferred alcohol components of the esters are up to C8 aliphatic alcohols, cyclohexanol, phenol or alkenyl alcohols.  The examples, which contain comparative data in which excessive pyrolysis temperatures have been used, describe the synthesis of alphacyanoacrylate esters of the following alcohols; methanol, isopropanol n-butanol, cyclo-hexanol, and octanol.  The resulting products find application as adhesives (see Divisions B5, C3 and C4).
Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
Postoperative hepatobiliary enzyme abnormalities often present as postoperative liver dysfunction in patients with gastric cancer (GC). This study aimed to identify the risk factors for postoperative liver dysfunction and their clinical impact after GC surgery. We retrospectively analyzed the data of 124 patients with GC who underwent laparoscopic or robotic surgery at Kyoto Prefectural University of Medicine between 2017 and 2019. Twenty (16.1%) patients with GC developed postoperative liver dysfunction (Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 ≥ Grade 3). Univariate analyses identified robotic surgery as a risk factor for postoperative liver dysfunction (P = 0.005). There was no correlation between the postoperative liver dysfunction status and postoperative complications or postoperative hospital stays. Patients with postoperative liver dysfunction did not have significantly worse overall survival (P = 0.296) or recurrence-free survival (P = 0.565) than those without postoperative liver dysfunction. Robotic surgery is a risk factor for postoperative liver dysfunction; however, postoperative liver dysfunction does not affect short or long-term outcomes.
PCT No. PCT/US95/13693 Sec. 371 Date Aug. 1, 1997 Sec. 102(e) Date Aug. 1, 1997 PCT Filed Oct. 19, 1995 PCT Pub. No. WO96/12478 PCT Pub. Date May 2, 1996Controlled delivery of a beneficial agent in a dispersion is provided using (i) a compressed core which contains the beneficial agent, a polymer which forms gelatinous microscopic particles upon hydration, and if desired, an agent to modulate the hydration; and (ii) a water insoluble coating which adheres to and surrounds the core and contains apertures which provide an area for the hydration and release of the dispersion. The release rate of the beneficial agent is a function of the number and size of the apertures in the coating.
Brain pathological changes impair cognition early in disease etiology. There is an urgent need to understand aging-linked mechanisms of early memory loss to develop therapeutic strategies and prevent the development of cognitive impairment. Tusc2 is a mitochondrial-resident protein regulating Ca2+ fluxes to and from mitochondria impacting overall health. We previously reported that Tusc2-/- female mice develop chronic inflammation and age prematurely, causing age- and sex-dependent spatial memory deficits at 5 months old. Therefore, we investigated Tusc2-dependent mechanisms of memory impairment in 4-month-old mice, comparing changes in resident and brain-infiltrating immune cells. Interestingly, Tusc2-/- female mice demonstrated a pro-inflammatory increase in astrocytes, expression of IFN-γ in CD4+ T cells and Granzyme-B in CD8+T cells. We also found fewer FOXP3+ T-regulatory cells and Ly49G+ NK and Ly49G+ NKT cells in female Tusc2-/- brains, suggesting a dampened anti-inflammatory response. Moreover, Tusc2-/- hippocampi exhibited Tusc2- and sex-specific protein changes associated with brain plasticity, including mTOR activation, and Calbindin and CamKII dysregulation affecting intracellular Ca2+ dynamics. Overall, the data suggest that dysregulation of Ca2+-dependent processes and a heightened pro-inflammatory brain microenvironment in Tusc2-/- mice could underlie cognitive impairment. Thus, strategies to modulate the mitochondrial Tusc2- and Ca2+- signaling pathways in the brain should be explored to improve cognitive health.
Sodium Chloride Injection, USP, 0.9% is a sterile, nonpyrogenic solution. The osmolarity is 300 mOsmol per liter (calculated).   


Each mL contains: Sodium chloride 9 mg; Water for Injection q.s. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single dose containers. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (pH 4.5-7.0).  


Sodium chloride occurs as colorless cubic crystals or white crystalline powder and has a saline taste. Sodium chloride is freely soluble in water. It is soluble in glycerin and slightly soluble in alcohol.  


The empirical formula for sodium chloride is NaCl and the molecular weight is 58.44.
An odor control fragrant additive comprises compacted pellets or granules infiltrated with fragrant oil. Cellulosic material, activated carbon and binder are mixed together and compacted to produce compacted pellets or granules. The cellulosic material preferably is peat moss, which swells up during absorption of fragrant oil and acts as fragrant oil storage. Fragrant oil is delivered to activated carbon that has large surface area, which evaporates the fragrance oil to release steady fragrance output. Thus, the activated carbon, which evaporates fragrance provides steady release of fragrance in the surrounding environment of fragrant compacted pellets or granules for a period of several months without overpowering the environment with excess fragrance. The fragrant compacted pellets or granules may be used to suppress malodor from trashcans or litter boxes and may provide stand-alone additions to drawers and cabinets, emitting pleasant fragrance.
BACKGROUND: Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiotherapy (SABR) delivered in just 5-fractions. Based on the known effectiveness of the accepted though invasive 2-fraction treatment method of high-dose-rate brachytherapy and given the ubiquity of prostate cancer, a further reduction in the number of treatments of external-beam SABR is possible. This study aims to evaluate the safety, efficacy, and non-inferiority of generalizable 2-fraction SABR compared to the current 5-fraction regimen.
METHODS: 502 patients will be enrolled on this phase II/III randomized control trial. Eligible patients will have previously untreated low- or favorable intermediate-risk adenocarcinoma of the prostate. Patients will be randomized between standard SABR of 40 Gy in 5 fractions given every-other-day and 27 Gy in 2 fractions at least two days apart but completing within seven days. MRI-based planning, radiopaque hydrogel spacer insertion, and fiducial marker placement are required, and SABR will be delivered on either a standard CT-guided linear accelerator or MR-LINAC. The primary endpoint will be freedom from disease progression, with additional secondary clinical, toxicity, and quality of life endpoints.
DISCUSSION: This study will be the largest prospective randomized trial, adequately powered to demonstrate non-inferiority, comparing 2-fraction SABR to standard 5-fraction SABR for localized prostate cancer. As the protocol does not obligate use of an MRI-LINAC or other adaptive technologies, results will be broadly generalizable to the wider community.
TRIAL REGISTRATION: This trial is registered on Clinicaltrials.gov: ClinicalTrials.gov Identifier: NCT06027892.
A system includes a learning filter for de-identified healthcare data. The system provides self-improved data filtering of data for detecting disease to allow patients to participate in observational studies to gather additional data. The processor performs operations including obtaining patient information about the patient and current order data. The current order data indicates an order for a laboratory test for the patient, and historical data indicating previous laboratory tests for the patient and results of the previous laboratory tests are obtained from a database. The operations further include determining that the patient is an object of interest for the disease by applying a filter to the historical data to generate filtered data and comparing the filtered data to a profile associated with the disease. Additional laboratory tests can be performed and then the hash-to-Patient Identifier (PID) mapping database and filters can be updated.
PURPOSE:To prepare a drink having high alkalinity, by applying clay mud to the surface of a heat-resistant formed article, drying the mud, contacting the article with charcoal, etc., in hot state to effect the carbonization of a part of the charcoal, etc., immersing in water before cooling, and removing the article and suspended material from the water. CONSTITUTION:Clay mud (e.g. secondary clay such as red clay, etc., or primary clay such as kaolin, etc.) is applied to the surface of a heat0resistant formed article, and dried. The article is heated at >=750 deg.C, made to contact with char coal or wood piece to effect the carbonization of at least a part of the charcoal, etc., and immersed in water before it is cooled to <=500 deg.C. The objective alkaline drink can be prepared by removing the article and suspended materials from the water. The calcination temperature of the clay should be >=750 deg.C since the adsorption of the charcoal components to clay is insufficient at <=750 deg.C, and the components can be adsorbed to the clay rapidly and firmly at >=800 deg.C. It can be prepared easily at a low cost.
Structured and remotely guided physical exercise program The participants in this group took part in a remote exercise program for 3 months, with three classes a week, each lasting 1 hour on alternate days. This group had a more active follow-up, with personalized instruction and ongoing support to improve their physical and emotional health.
Background and Objectives: Ventilator-associated pneumonia (VAP) is a common complication in critically ill patients receiving mechanical ventilation. The incidence rates of VAP vary, and it poses significant challenges due to microbial resistance and the potential for adverse outcomes. This study aims to explore the microbial profile of VAP and evaluate the utility of biomarkers and illness severity scores in predicting survival. Materials and Methods: A retrospective cohort study was conducted involving 130 patients diagnosed with VAP. Microbial analysis of bronchoalveolar lavage (BAL) fluid, as well as measurements of C-reactive protein (CRP) and procalcitonin (PCT) levels, were performed. Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were calculated to assess illness severity. Statistical analyses were conducted to determine correlations and associations. Results: The study revealed that Klebsiella pneumoniae (K. pneumoniae) (50.7%) and Pseudomonas aeruginosa (P. aeruginosa) (27.69%) were the most identified microorganisms in VAP cases. SOFA (p-value < 0.0001) and APACHE II (p-value < 0.0001) scores were effective in assessing the severity of illness and predicting mortality in VAP patients. Additionally, our investigation highlighted the prognostic potential of CRP levels (odds ratio [OR]: 0.980, 95% confidence interval [CI] 0.968 to 0.992, p = 0.001). Elevated levels of CRP were associated with reduced survival probabilities in VAP patients. Conclusion: This study highlights the microbial profile of VAP and the importance of biomarkers and illness severity scores in predicting survival. Conclusions: The findings emphasize the need for appropriate management strategies to combat microbial resistance and improve outcomes in VAP patients.
A female of reproductive age presents to the emergency department with progressive dyspnoea due to pneumothorax. She has a history of lymphangioleiomyomatosis (LAM) diagnosed by lung biopsy 15 years ago following incidental finding of pneumothorax. Despite various procedural and medicinal treatments, she continued to have recurrent pneumothorax, with three hospital admissions over the preceding 3 months. LAM is a rare cystic lung disease affecting the lymphatic system, which most commonly affects women of childbearing age. It can be diagnosed via imaging or tissue biopsy (gold standard). Treatment can be difficult, and it often requires highly specialised care by pulmonologists and often confers significant limitations to patients' independence and quality of life. Family physicians are often part of multidisciplinary team to provide care to patients with rare chronic conditions.
The invention discloses a 2-amino-3-perfluoro acetoindole compound and its derivative, a preparation method and an application thereof. The compound has the chemical structural general formula defined in the specification, wherein R represents a monosubstituent, a disubstituent, a trisubstituent or a tetrasubstituent on a phenyl ring. The substituent is H, F, Cl, Br, nitro or C1-C3 alkyloxy. The derivative has the chemical structural general formula defined in the specification, wherein R is the same as mentioned above; and R1 is acetonyl, C1-C4 alkyl or C1-C4 nonsaturated alkyl. The compound is prepared by a reaction between the 2-amino-3-perfluoro acetoindole compound and trifluoroactic anhydride. The derivative is prepared by a reaction between the 2-amino-3-perfluoro acetoindole compound and a Grignard reagent or acetone. The 2-amino-3-perfluoro acetoindole compound and its derivative provided by the invention can be applied as an HIV reverse transcriptase inhibitor.
OBJECTIVE: There have been reports of neuromyelitis optica spectrum disorder (NMOSD) coexisting with connective tissue disorders. The objective of this study was to describe the characteristics of NMOSD coexisting with autoimmune diseases (AID).
METHODS: This retrospective study evaluated NMOSD patients with and without AID. The enrolled patients had at least one attack, with duration of more than 1 year. Data on the demographics, clinical features, and laboratory findings were assessed. The Poisson model was used to investigate the risk factors associated with the annualized relapse rate (ARR), whereas the Cox model was used to evaluate the risk factors for the first relapse.
RESULTS: A total of 180 patients (154 women and 26 men) with NMOSD were identified: 45 had AID and 135 did not. Female patients had a higher prevalence of concomitant AID (p = 0.006) and a greater relapse rate within the first year. There were no statistically significant differences in the characteristics of patients. Kaplan-Meier analysis revealed that NMOSD patients with seropositive aquaporin 4 antibodies (AQP4-Ab; log-rank: p = 0.044), had a shorter time to relapse. Patients seropositive for AQP4-Ab (HR = 2.402, 95%CI = 1.092-5.283, p = 0.029) had a higher risk of suffering a first relapse, according to the Cox model. Patients with and without AID showed a similar declining tendency in terms of change in ARR throughout the first 5 years of the disease. The ARR was greater in the first year [incidence rate ratio (IRR) = 1.534, 95%CI = 1.111-2.118] and the first 2 years (IRR = 1.474, 95%CI = 1.056-2.058) in patients with coexisting AID diagnosis prior to the NMOSD onset.
CONCLUSIONS: Patients with NMOSD with coexisting AID had similar characteristics when compared with those without AID. NMOSD patients with AID diagnosed before onset had a higher risk of relapse in the early stage of the disease.
FIELD: medicine, physiotherapy. SUBSTANCE: method involves preparing curative extract from slimy sludge of continental lakes. Method involves dissolving dehydrated native curative sludge in 96% ethanol at heating to 35-40 C, sterilization in extractor by feeding gaseous carbon dioxide under pressure 66 atm, keeping under this pressure followed by abrupt pressure drop to atmospheric one. Extraction is carried out by feeding liquid carbon dioxide, spirituous miscell is settled, solvent is distilled off at simultaneous extract dissolving in oil. The end extract properties correspond to that of tambukan sludge. EFFECT: improved method of extract preparing.
The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.
A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.